New targets in the treatment of anorexia nervosa

Bibliography

• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th ed). American Psychiatric Association, Washington, DC (1994):539–545.
   Google Scholar
• AGRAS WS, BRANDT HA, BULIK CM et al.: Report of the National Institutes of Health Workshop on overcoming barriers to treatment research in anorexia nervosa. Int.,/ Eat. Disord. (2004) 35:509–521.
   PubMed Web of Science ®Google Scholar
• •Consensus on future research in AN.
   Google Scholar
• HARRIS EC, BARRACLOUGH B: Suicide as an outcome for mental disorders. A meta-analysis. BE J. Psychiatry (1997) 170:205–228.
   PubMed Web of Science ®Google Scholar
• HARRIS EC, BARRACLOUGH B: Excess mortality of mental disorders. Br. J. Psychiatry (1998) 173:11–53.
   PubMed Web of Science ®Google Scholar
• SULLIVAN PF: Mortality in anorexia nervosa. Am. J. Psychiatry (1995) 152:1073–1074.
   PubMed Web of Science ®Google Scholar
• BARBARICH NC, KAYE WH, JIMERSON D: Neurotransmitter and imaging studies in anorexia nervosa: new targets for treatment. Curr. Drug Targets CNS Neurol Disord. (2003) 2:61–72.
   PubMedGoogle Scholar
• •Review of NT and imaging studies in AN.
   Google Scholar
• CASPER RC: Personality features of womenwith good outcome from restricting anorexia nervosa. Psychosom. Med. (1990) 52:156–170.
   PubMed Web of Science ®Google Scholar
• SRINIVASAGAM NM, KAYE WH, PLOTNICOV KH, GREENO C, WELTZIN TE, RAO R: Persistent perfectionism, symmetry, and exactness after long-term recovery from anorexia nervosa. Am. J. Psychiatry (1995) 152:1630–1634.
   PubMed Web of Science ®Google Scholar
• STROBER M: Personality and symptomatological features in young, nonchronic anorexia nervosa patients. Psychosom. Res. (1980) 24:353–359.
   PubMed Web of Science ®Google Scholar
• DAVIS C, KAPTEIN S, KAPLAN A, OLMSTED M, WOODSIDE DB: Obsessionality in anorexia nervosa: the moderating influence of exercise. Psychosomatic Medicie (1998) 60:192–197.
   PubMed Web of Science ®Google Scholar
• HALMI KA, ECKERT E, MARCHI P, APPLE R, COHEN J: Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch. Gen. Psychiatry (1991) 48:712–719.
   PubMed Web of Science ®Google Scholar
• LAESSLE RG, KITTL S, FICHTER M, WITTCHEN HU, PIRKE KM: Major affective disorder in anorexia nervosa and bulimia: A descriptive diagnostic study. Br. J. Psychiatry (1987) 151:785–790.
   PubMed Web of Science ®Google Scholar
• TONER BB, GARFINKEL PE, GARNER DM: Affective and anxiety disorders in the long-term follow-up of anorexia nervosa. Int. J. Psychiatry Med. (1988) 18:357–360.
   PubMed Web of Science ®Google Scholar
• GERSHON E, SCHREIBER J, HAMOVIT J et al.: Clinical findings in patients with anorexia nervosa and affected illnesses in their relatives. Am. J. Psychiatry (1984) 149:1419–1422.
   Google Scholar
• BRAUN DL, SUNDAY SR, HALMI KA: Psychiatric comorbidity in patients with eating disorders. Psycho]. Med. (1994) 24:859–867.
   PubMed Web of Science ®Google Scholar
• HERZOG DB, KELLER MB, LAVORI PW, KENNY GM, SACKS NR: The prevalence of personality disorders in 210 women with eating disorders. J. Clin. Psychiatry (1992) 53:147–152.
   PubMed Web of Science ®Google Scholar
• IVARSSON T, RASTAM M, WENTZ E, GILLBERG I, GILLBERG C: Depressive disorders in teenage-onset anorexia nervosa: a controlled longitudinal, partly community-based study. Compr. Psychiatry (2000) 41:398–403.
   PubMed Web of Science ®Google Scholar
• BULIK CM, SULLIVAN PF, FEAR JL, JOYSE PR: Eating disorders and antecedent anxiety disorders: a controlled study. Acta Psychiatr. Scand. (1997) 96:101–107.
   PubMed Web of Science ®Google Scholar
• PLA C, TORO J: Anorexia nervosa in a Spanish adolescent sample: an 8year longitudinal study. Acta. Psychiatr. Scand. (1999) 100:441–446.
   PubMed Web of Science ®Google Scholar
• GODART NT, FLAMENT M, LECRUBIER Y, JEAMMET P: Anxiety disorders in anorexia nervosa and bulimia' nervosa: co-morbidity and chronology of appearance. Eur. Psychiatry (2000) 15:38–45.
   PubMed Web of Science ®Google Scholar
• THORNTON C, RUSSELL J: Obsessive-compulsive comorbidity in the eating disorders. Int. .1. Eat. Disord. (1997) 21:83–87.
   Google Scholar
• MACDONALD C: Treatment resistance in anorexia nervosa and the pervasiveness of ethics in clinical decision making. Can. J. Psychiatry (2002) 47:267–270.
   PubMed Web of Science ®Google Scholar
• TREASURE J, CAMPBELL I: The case for biology in the aetiology of anorexia nervosa. Psycho] Med. (1994) 24:3–8
   PubMed Web of Science ®Google Scholar
• •Review of biological data in AN.
   Google Scholar
• SZABO ST, GOULD TD, MANJI HK: Neurotransmitters, receptors, signal transduction, and second messengers in psychiatric disorders. In: Textbook of Psychopharmacology Ord Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc, Washington, DC (2004):3–52.
   Google Scholar
• •Review of psychopharmacology principles.
   Google Scholar
• BLUNDELL JE: Serotonin and appetite. Neuropharmacology (1984) 23:1537–1551.
   PubMed Web of Science ®Google Scholar
• LEIBOWITZ SF, SHOR-POSNER G: Brain serotonin and eating behavior. Appetite. (1986) 7(Suppl.):1–14.
   Google Scholar
• BREWERTON T: Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology (1995) 20:561–590.
   PubMed Web of Science ®Google Scholar
• KAYE WH, EBERT MH, RALEIGH M, LAKE R: Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch. Gen. Psychiatry (1984) 41:350–355.
   PubMed Web of Science ®Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT, JIMERSON DC, EBERT MH: CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol. Psychiatry (1988) 23:102–105.
   PubMed Web of Science ®Google Scholar
• HADIGAN CM, WALSH BT, BUTTINGER C, HOLLANDER E: Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa. Biol. Psychiatry (1995) 37:504–511.
   PubMed Web of Science ®Google Scholar
• FRANK GK, KAYE WH, MELTZER CC et al.: Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol. Psychiatry (2002) 52:896–906.
   PubMed Web of Science ®Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT, EBERT MH: Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch. Gen. Psychiatry (1991) 48:556–62.
   Google Scholar
• FRANK GK, KAYE WH, WELTZIN TE et al: Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. Int. J. Eat. Disord. (2001) 30:57–68.
   PubMed Web of Science ®Google Scholar
• KAYE WH, BARBARICH NC, PUTNAM K et al.: Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. Int. J. Eat. Disord. (2003) 33:257–267.
   PubMed Web of Science ®Google Scholar
• SZABO ST, BLIER P: Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA (A) receptors: a microiontophoretic study in the rat locus cemleus. Synapse (2001) 42:203–212.
   PubMed Web of Science ®Google Scholar
• FERGUSON CP, LA VIA MC, CROSSAN PJ, KAYE WH: Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int. .1. Eat. Disord. (1999) 25:11–17.
   PubMed Web of Science ®Google Scholar
• •An antidepressant efficacy review.
   Google Scholar
• ATTIA E, HAIMAN C, WALSH BT, FLATER SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155:548–551.
   Google Scholar
• •An efficacy study of fluoxetine in acute AN.
   Google Scholar
• BARBARICH NC, MCCONAHA CW, HALMI KA et al.: Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int. J. Eat. Disord. (2004) 35:10–15.
   PubMed Web of Science ®Google Scholar
• •A double-blind, controlled trial.
   Google Scholar
• ANDERSON IM, PARRY-BILLINGS M, NEWSHOLME EA, FAIRBURN CG, COWEN PJ: Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psycho] Med. (1990) 20:785–791
   PubMed Web of Science ®Google Scholar
• FAVARO A, CAREGARO L, BURLINA AB, SANTONASTASO P: Tryptophan levels, excessive exercise, and nutritional status in anorexia nervosa. Psychosom. Med. (2000) 62:535–538.
   PubMed Web of Science ®Google Scholar
• KAYE WH, FRANK GK, MCCONAHA C: Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology (1999) 21:503–506.
   PubMed Web of Science ®Google Scholar
• WATANABE T, TAGUCHI Y, MAEYAMA K: Enzymes involved in histamine metabolism. In: Histaminergic Neurons: Morphology and Function. Watanabe T, Wada H (Eds), CRC Press, Boca Raton (1991):11–34.
   Google Scholar
• RICHELSON E: Histamine receptors in the central nervous system. In: The Histamine Receptor. Schwartz J, Haas HL (Eds), Wiley-Liss, Inc, New York (1992):271–295.
   Google Scholar
• GLAESER BS, MAHER TJ, WURTMAN RJ: Changes in brain levels of acidic, basic, and neutral amino acids after consumption of single meals containing various proportions of protein. Neurochem. (1983) 41:1016–1021.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JC, LAMPART C, ROSE C: Histamine formation in rat brain in vivo: effects of histidine loads. .1 Neurochem. (1972) 19:801–810.
   PubMed Web of Science ®Google Scholar
• ITOWI N, NAGAI K, NAKAGAWA H, WATANABE T, WADA H: Changes in the feeding behavior of rats elicited by histamine infusion. Physic] Behav. (1988) 44:221–226.
   PubMed Web of Science ®Google Scholar
• SHEINER JB, MORRIS P, ANDERSON GH: Food intake suppression by histidine. Pharmacol Biochem. Behav. (1985) 23:721–726.
   PubMed Web of Science ®Google Scholar
• FUKAGAWA K, SAKATA T, SHIRAISHI T et al.: Neuronal histamine modulates feeding behavior through Hl-receptor in rat hypothalamus. J. Am. Physiol. Soc. (1989) 89:R605–R611.
   Google Scholar
• OISHI R, NISHIBORI M, LTOH Y, SHISHIDO S, SAEKI K: Is monoamine turnover in the brain regulated by histamine H3 Receptors. Eur..1. Pharmacol (1990) 184:135–142.
   PubMed Web of Science ®Google Scholar
• MERCER LP, SAXON KELLY D, HUMPHRIES LL, DUNN JD: Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats../. Nutr. (1994) 124:1029–1036.
   PubMed Web of Science ®Google Scholar
• MERCER LP, DODDS SJ, SCHWEISTHAL MR, DUNN JD: Brain histidine and food intake in rats fed diets deficient in single amino acids. Nutr. (1989)11:66–74.
   Google Scholar
• PAO SK, DICKERSON JW: Effect of a low protein diet and isoenergetic amounts of a high protein diet in the weanling rat on the free amino acids of the brain. Nut]: Metabol (1975) 18:204–216.
   PubMedGoogle Scholar
• LUNN PG, AUSTIN S: Differences in nitrogen metabolism between protein-deficient and energy deficient rats with similarly restricted growth rates. Ann. Nutr. Metab. (1983) 27:242–251.
   PubMed Web of Science ®Google Scholar
• MERCER LP, KELLEY DS, HAQ A, HUMPHRIES LL: Dietary induced anorexia: a review of involvement of the histaminergic system. J. Am. Coll Nutr. (1996) 15:23–230.
   Web of Science ®Google Scholar
• TAYLOR DM, McASKILL R: Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatrica Scandinavica (2000). 101:416–432.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, MANCINI DA, BASILE VS: Mechanisms of antipsychotic-induced weight gain. J. Clin. Psychiat. (2001) 62\(Suppl. 23):23–29.
   Google Scholar
• WETTERLING T: Body weight gain with atypical antipsychotics: A comparative review. Drug Sal (2001) 24:59–73.
   PubMed Web of Science ®Google Scholar
• WEINSIER RL, HUNTER GR, HEINI AF, GORAN MI, SELL SM: The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am. J. Med. (1998) 105:145–150.
   PubMed Web of Science ®Google Scholar
• BAPTISTA T, LACRUZ A, ANGELES F et al.: Endocrine and metabolic profile in the obesity associated to typical antipsychotic drug-administration. Pharmacopsychiatry (2001) 34:223–231.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, MANCINI DA, BASILE VS: Mechanisms of antipsychotic-induced weight gain. J. Clin. Psychiat. (2001) 62\(Suppl. 23):23–29.
   Google Scholar
• KROEZE WK, HUFEISEN SJ, POPADAK BA et al.: Hl-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28:519–526.
   PubMed Web of Science ®Google Scholar
• MULLER DJ, MUGLIA P, FORTUNE T,KENNEDY JL: Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res. (2004) 49:309–329.
   PubMed Web of Science ®Google Scholar
• POWERS PS, BANNON Y, EUBANKS R. Anorexia nervosa and atypical antipsychotics: effect on weight and psychopathology. Eating Disorders Research SocitV annual meeting Ravello Italy (2003):65.
   Google Scholar
• VANDEREYCKEN W, PIERLOOT R: Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr. Scand. (1982) 66(6):445–450.
   PubMed Web of Science ®Google Scholar
• ••A controlled trial of an antipsychoticin AN.
   Google Scholar
• VANDEREYCKEN W: Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br. J. Psychiatry (1984) 144:288–292.
   PubMed Web of Science ®Google Scholar
• ••A controlled trial of an antipsychoticin AN.
   Google Scholar
• DALLY P, SARGANT W: A new treatmentof anorexia nervosa. Br. Med. J. (1960) 1:1770–1773.
   PubMed Web of Science ®Google Scholar
• GARDOS G, COLE JO: Overview: public health issues in tardive dyskinesia. Am. J. Psychiatry (1980) 137:776–781.
   PubMed Web of Science ®Google Scholar
• DULCAN MK, BREGMAN J, WELLER EB, WELLER R: Treatment of childhood and adolescent disorders. In: Essentials of Clinical Psychopharmacology. Schatzberg AF, Nemeroff CB, American Psychiatric Publishing, Inc. Washington DC (2001):459–517.
   Google Scholar
• CONDON JT: Long-term neuroleptic therapy and chronic anorexia nervosa complicated by tardive dyskinesia. A case report. Acta Psychiatr. Scand. (1986) 73:203–206.
   PubMed Web of Science ®Google Scholar
• WEIZMAN A, TYANO S, WIJSENBEEK H, BEN DAVID M: Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychother. Psychosom. (1985) 43:136–140.
   PubMed Web of Science ®Google Scholar
• MARDER SR, WIRSHING DA: Clozapine. In: Textbook of Psychopharmacology Ord Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc. Washington DC (2004):443–456.
   Google Scholar
• KAPUR S, SRIDHAR N, REMINGTON G: The newer antipsychotics: underlying mechanisms and the new clinical realities. Curr. Opin. Psychiatry (2004) 17:115–122.
   Web of Science ®Google Scholar
• HARVEY PD, KEEFE RS: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry (2001) 158:176–184.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, MCGURK SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. (1999) 25:233–255.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, SUMIYOSHI T: Atypical antipsychotic drugs improve cognition in schizophrenia. Biol. Psychiatry (2003) 53:265–270.
   PubMed Web of Science ®Google Scholar
• GREEN MF, MARDER SR, GLYNN SM et al.: The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biological Psychiatry (2002) 51:972–978.
   PubMed Web of Science ®Google Scholar
• CARPENTER WT, GOLD JM: Another view of therapy for cognition in schizophrenia. Biological Psychiatry (2002) 51:969–971.
   PubMed Web of Science ®Google Scholar
• BILDER RM, GOLDMAN RS, VOLAVKA J et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Pyschiatry (2002) 159:1018–1028.
   PubMed Web of Science ®Google Scholar
• KEEFE RS, SEIDMAN LJ, CHRISTENSEN BK et al: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Pyschiatry (2004) 161:985–995.
   PubMed Web of Science ®Google Scholar
• HALMI KA, ECKERT E, FALK JR: Cyproheptadine for anorexia nervosa. Lancet (1982) 1:1357–1358.
   PubMed Web of Science ®Google Scholar
• MASAN PS: Atypical antipsychotics in the treatment of affective symptoms: a review. Ann. Clin. Psychiatry (2004) 16:3–13.
   PubMedGoogle Scholar
• GOLDEN RN, DAWKINS K, NICHOLS L: Trazodone and nefazodone. In: Textbook of Psychopharmacology Ord Erin Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc. Washington, DC (2004):315–326.
   Google Scholar
• CASSANO GB, MINIATI M, PINI S et al.: Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int. J. Eat. Disord. (2003) 33:172–177.
   PubMed Web of Science ®Google Scholar
• NINAN PT, MUNTASSER S: Buspirone and gepirone. In: Textbook of Psychopharmacology Ord Erin). Schatzberg AF, Nemeroff CB. (Ed.), American Psychiatric Publishing, Inc. Washington, DC (2004):391–404.
   Google Scholar
• KAYE WH, NAGATA T, WELTZIN TB et al.: Double-blind, placebo-controlled, administration of fluoxetine in restricting-and purging-type anorexia nervosa. Biol. Psychiatry (2001) 49:644–652.
   PubMed Web of Science ®Google Scholar
• ROSENBAUM JF, TOLLEFSON GD: Fluoxetine. In: Textbook of Psychophannacology Ord Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc. Washington, DC (2004):231–146.
   Google Scholar
• FLORES BH, SCHATZBERG AF: Mirtazapine. In: Textbook of Psychophannacology Ord Ed). Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, DC (2004):341–348.
   Google Scholar
• SCHULE C, BAGHAI T, ZWANZGER P et al.: Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychophannacology (2003) 166:271–275.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, BLUNDELL JE: The neurobiological basis of eating disorders: some formulations. Biol. Psychiatry (1988) 23:53–78.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, WOODS SC, PORTE D JR, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661–671.
   PubMed Web of Science ®Google Scholar
• JIMERSON DC, WOLFE BE, NAAB S: In: Anorexia nervosa and bulimia nervosa. Coffee CE, Brumback RA (Eds), American Psychiatric Press Inc., Washington DC (1998):563–578
   Google Scholar
• STOVING RK, HANGAARD J, HANSEN-NORD M, HAGEN C: A review of endocrine changes in anorexia nervosa. J. Psychiatr. Res. (1999) 33:139–152.
   PubMed Web of Science ®Google Scholar
• VALE W, SPIESS J, RIVIER C, RIVIER J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 213:1394–1397.
   PubMed Web of Science ®Google Scholar
• GOLD PW, GWIRTSMAN H, AVGERINOS PC et al: Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl. J. Med. (1986) 314:1335–1342.
   Google Scholar
• KAYE WH, GWIRTSMAN HE, GEORGE DT et al.: Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. I Clin. EndocrinoL Metab. (1987) 64:203–208.
   PubMed Web of Science ®Google Scholar
• LICINIO J, WONG ML, GOLD PW: The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Res. (1996) 62:75–83.
   PubMed Web of Science ®Google Scholar
• WALSH BT, ROOSE SP, KATZ JL et al:Hypothalamic-pituitary-adrenal-cortical activity in anorexia nervosa and bulimia. Psychoneuroendocrinology (1987) 12:131–140.
   PubMed Web of Science ®Google Scholar
• GLOWA JR, GOLD PW: Corticotropin releasing hormone produces profound anorexigenic effects in the rhesus monkey. Neuropeptides (1991) 18:55–61.
   PubMed Web of Science ®Google Scholar
• RIVIER C, VALE W: Corticotropin-releasing factor (CRF) acts centrally to inhibit growth-hormone secretion in the rat. Endocrinology (1984) 114:2409–2411.
   PubMed Web of Science ®Google Scholar
• SIRINATHSINGHJI DJ: Inhibitory influence of corticotropin releasing factor on components of sexual behaviour in the male rat. Brain Res. (1982) 407:185–190.
   Google Scholar
• SUTTON RE, KOOB GF, LeMOAL M, RIVIER J, VALE W: Corticotropin releasing factor produces behavioral activation in rats. Nature (1982) 297:331–333.
   PubMed Web of Science ®Google Scholar
• ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. ./. Psychiatr. Res. (2000) 34:171–181.
   PubMed Web of Science ®Google Scholar
• PLOTSKY PM: Pathways to the secretion of adrenocorticotropin: a view from the portal. J. Neuroendocrinol (1991) 3:1–9.
   PubMed Web of Science ®Google Scholar
• HOLSBOER F: Neuroendocrinology of mood disorders. In: Psychopharinacology: the fourth generation of progress. Bloom FE, Kupfer DJ (Eds), Raven Press, New York (1995):957–969.
   Google Scholar
• OWENS MJ, NEMEROFF CB: Physiology and pharmacology of corticotropin-releasing factor. Phannacol Rev. (1991) 43:425–473.
   PubMed Web of Science ®Google Scholar
• HOLSBOER F, SPENGLER D, HEUSER I: The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog. Brain Res. (1992) 93:385–417.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, LEVINE AS, GOSNELL BA, MITCHELL JE, KRAHN DD, NIZIELSKI SE: Peptides and feeding. Peptides (1985) 6\(Suppl. 2):181–192.
   Google Scholar
• BREWERTON TD, LYDIARD RB, LARAIA MT, SHOOK JE, BALLENGER JC: CSF beta-endorphin and dynorphin in bulimia nervosa. Ain. J. Psychiatry (1992) 149:1086-1090. mg. KAYE WH, BERRETTINI WH, GWIRTSMAN HE et al.: Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including beta-endorphin) in anorexia nervosa. Life Sci. (1987) 41:2147–2155.
   Google Scholar
• LESEM MD, BERRETTINI WH, KAYE WH, JIMERSON DC: Measurement of CSF dynorphin A 1-8 immunoreactivity in anorexia nervosa and normal-weight bulimia. Biol. Psychiatry (1991) 29:244–252.
   PubMed Web of Science ®Google Scholar
• BRAMBILLA F, BRUNETTA M, PEIRONE A et al: T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. anorexia nervosa. Psychiatry Res. (1995) 59:43–50.
   PubMedGoogle Scholar
• KALRA SP, DUBE MG, FOURNIER A, KALRA PS: Structure-function analysis of stimulation of food intake by neuropeptide Y: effects of receptor agonists. Physiol Behav. (1991) 50:5–9.
   PubMed Web of Science ®Google Scholar
• KAYE WH, BERRETTINI W, GWIRTSMAN H, GEORGE DT: Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. Arch. Gen. Psychiatry (1990) 47:548–556.
   PubMed Web of Science ®Google Scholar
• BARANOWSKA B, WOLINSKA-WITORT E, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, CHMIELOWSKA M: Plasma leptin, neuropeptide Y (NPY) and galanin concentrations in bulimia nervosa and in anorexia nervosa. Neuroendocrinol Lett. (2001) 22:356–358.
   PubMed Web of Science ®Google Scholar
• KORNER J, LEIBEL RL: To eat or not to eat - how the gut talks to the brain. N Engl. J. Med. (2003) 349:926–928.
   PubMed Web of Science ®Google Scholar
• NEARY NM, SMALL C J, BLOOMS R: Gut and mind. Gut (2003) 52:918–921.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, LONGOBARDI N, FUSCHINO A, FABRAZZO M, MAJ M: Peripheral ghrelin and PYY responses to food intake and short term fasting implications for eating behavior and gastrointestinal physiology in Bulimia nervosa. Eating Disorders Research Socieh, annual meeting Ravello Italy (2003):40.
   Google Scholar
• BATTERHAM RL, COWLEY MA, SMALL CAROLINE J et al: Gut hormone ''3-36 physiologically inhibits food intake. Nature (2002) 418:650–654.
   PubMed Web of Science ®Google Scholar
• •A study of PYY3–36 in human subjects.
   Google Scholar
• BATTERHAM RL, COHEN A, ELLIS SM et al.: Inhibition of food intake in obese subjects by Peptide YY3_36. N Engl. J. Med. (2003) 349:941–948.
   PubMed Web of Science ®Google Scholar
• •A study of PYY3–36 in human subjects.
   Google Scholar
• HORVATH TL, DIANO S, SOTONYI P, HEIMAN M, TSCHO MP: Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 142:4163-4169.
   Google Scholar
• •A ghrelin review.
   Google Scholar
• WREN AM, SEAL LJ, COHEN MA et al: Ghrelin enhances appetite and increases food intake in humans. I Clin. Endocrinol Metab. (2001) 86:5992–5995.
   PubMed Web of Science ®Google Scholar
• •A study of ghrelin administration to human subjects.
   Google Scholar
• OTTO B, CUNTZ U, FRUEHAUF E et al.: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. Endocrinol (2001) 145:669–673.
   PubMed Web of Science ®Google Scholar
• CUMMINGS DE, SHANNON MH: Roles for ghrelin in the regulation of appetite and body weight. Arch Surg. (2003) 138:389–396.
   PubMed Web of Science ®Google Scholar
• KEIRE DA, MANNON P, KOBAYASHI M, WALSH JH, SOLOMON TE, REEVE JR: Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am. J. Physiol Gastrointest Liver Physiol (2000) 279:G126–G131.
   Web of Science ®Google Scholar
• BROBERGER C, LANDRY M, WONG H, WALSH JN, HOKFELT T: Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology (1997) 66:393–408.
   PubMed Web of Science ®Google Scholar
• GIBBS J, YOUNG RC, SMITH GP: Cholecystokinin decreases food intake in rats../. Comp. Physiol Psycho]. (1973) 84:488–495.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GERTZ BJ, KANAYAMA S et al.: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. j Clin. Invest. (1989) 84:1220–1225.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, MORITA ET, CONRAD CK, WILLIAMS JA: Regulation of gastric emptying in humans by cholecystokinin. Clin. Invest. (1986) 77:992–996.
   Google Scholar
• TAMAI H, TAKEMURA J, KOBAYASHI N, MATSUBAYASHI S, MATSUKURA S, NAKAGAWA T: Changes in plasma cholecystokinin concentrations after oral glucose tolerance test in anorexia nervosa before and after therapy. Metabolism (1993) 42:581–584.
   PubMed Web of Science ®Google Scholar
• HARTY RF, PEARSON PH, SOLOMON TE, MCGUIGAN JE: Cholecystokinin, vasoactive intestinal peptide and peptide histidine methionine responses to feeding in anorexia nervosa. Regul Pept. (1991) 36:141–150.
   PubMedGoogle Scholar
• BARANOWSKA B, RADZIKOWSKA M, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, BOROWIEC M: Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes. Metab. (2000) 2:99–103.
   PubMedGoogle Scholar
• PIRKE KM, KELLNER MB, FRIESS E, KRIEG JC, FICHTER MM: Satiety and cholecystokinin. Int. J. Eat. Disord. (1994) 15:63–69.
   PubMed Web of Science ®Google Scholar
• GIBBS J, SMITH GP: Satiety: the roles of peptides from the stomach and the intestine. Fed Proc. (1986) 45:1391–1395.
   PubMedGoogle Scholar
• GUTZWILLER JP, DREWE J, HILDEBRAND P, ROSSI L, LAUPER JZ, BEGLINGER C: Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology (1994) 106:1168–1173.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GERTZ BJ, KANAYAMA S et al.: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. Clin. Invest. (1989) 84:1220–1225.
   PubMed Web of Science ®Google Scholar
• KISSILEFF HR, VAN ITALLIE TB: Physiology of the control of food intake. Ann. Rev Num. (1982) 2:371–418.
   PubMed Web of Science ®Google Scholar
• PEIKIN SR: Role of cholecystokinin in the control of food intake. Gastroenterol North Am. (1989) 18:757–775.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, GOLDFINE ID, ROSEN MS, TAPLITZ RA, WILLIAMS JA: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Chit. Invest. (1985) 75:1144–1152.
   Google Scholar
• LIDDLE RA, GOLDFINE ID, WILLIAMS JA: Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology (1984) 87:542–549.
   PubMed Web of Science ®Google Scholar
• MORAN TH, AMEGLIO PJ, PEYTON HJ, SCHWARTZ GJ, MCHUGH PR: Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. Am. J. Physiol (1993) 265(3 Pt 2):R620–R624.
   Google Scholar
• MORAN TH, AMEGLIO PJ, SCHWARTZ GJ, MCHUGH PR: Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am. J. Physiol (1992) 262(1 Pt 2):R46–R50.
   Google Scholar
• BEGLINGER C, DEGEN L, MATZINGER D, D'AMATO M, DREWE J: Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am. I Physiol Regul Integr Comp Physiol (2001) 280:R1149–R1154.
   Web of Science ®Google Scholar
• LIEVERSE RJ, MASCLEE AA, JANSEN JB, ROVATI LC, LAMERS CB: Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. Biol. Psychiatry (1995) 37:331–335.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372:425–432.
   PubMed Web of Science ®Google Scholar
• PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 269:540–543.
   PubMed Web of Science ®Google Scholar
• HALAAS JL, GAJIWALA KS, MAFFEI M et al: Weight reducing effects of the plasma protein encoded by the obese gene. Science (1995) 269:543–546.
   PubMed Web of Science ®Google Scholar
• CAMPFIELD LA, SMITH FJ, GUISEZ Y, DEVOS R, BURN P: Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science (1995) 269:546–549.
   PubMed Web of Science ®Google Scholar
• MONTAGUE CT, FAROOQI IS, WHITEHEAD JP et al.: Congenital leptin deficiency is associated with severe early onset obesity in humans. Nature (1997) 387:903–908.
   PubMed Web of Science ®Google Scholar
• CONSIDINE RV, CONSIDINE EL, WILLIAMS CJ, HYDE TM, CARO JF: The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes (1996) 45:992–994.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MW, PESKIND E, RASKIND M, BOYKO EJ, PORTE D J: Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat. Med. (1996) 2:589–593.
   PubMed Web of Science ®Google Scholar
• CONSIDINE RV, SINHA MK, HEIMAN ML et al: Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl. I Med. (1996) 334:292–295.
   PubMed Web of Science ®Google Scholar
• ECKERT ED, POMEROY C, RAYMOND N, KOHLER PF, THURAS P, BOWERS CY: Leptin in anorexia nervosa../. Clin. Endocrinol Metab. (1998) 83:791–795.
   PubMed Web of Science ®Google Scholar
• MANTZOROS C, FLIER JS, LESEM MD, BREWERTON TD, JIMERSON DC: Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain. J. Clin. Endocrinol Metab. (1997) 82:1845–1851.
   PubMed Web of Science ®Google Scholar
• EXNER C, HEBEBRAND J, REMSCHMIDT H, WEWETZER C, ZIEGLER A, HERPERTZ S: Leptin suppresses semi-starvation-induced hyperactivity in rats: implications for anorexia nervosa. Ma. Psychiatry (2000) 5:476–481.
   Google Scholar
• HOLTKAMP K, HERPERTZ-DAHLMANN B, MIKA C, HEER M, HEUSSEN N, FICHT HERPERTZ S: Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa. J. Clin. Endocrinol Metab. (2003) 88:5169–5174.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, LONG OBARDI N, FUSCHINO A, FABRAZZO M, MAJ M: Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. I Clin. Psychopharmacol (2002) 22:424–426.
   Google Scholar
• FREDERICH R, HU S, RAYMOND N, POMEROY C: Leptin in anorexia nervosa and bulimia nervosa: importance of assay technique and method of interpretation. Lab. Clin. Med. (2002) 139:72–79.
   PubMed Web of Science ®Google Scholar
• JIMERSON DC: Leptin and the neurobiology of eating disorders.' Lab. Clin. Med. (2002) 139:70–71.
   PubMed Web of Science ®Google Scholar
• HOLTKAMP K, HEBEBRAND J, MIKA C, HEER M, HEUSSEN N, HERPERTZ-DAHLMANN B: High serum leptin levels subsequent to weight gain predict renewed weight loss in patients with anorexia nervosa. Psychoneuroendocrinology (2004) 29:791–797.
   PubMedGoogle Scholar
• GENDALL KA, KAYE WH, ALTEMUS M, MCCONAHA CW, LA VIA MC: Leptin, neuropeptide Y, and peptide YY in long-term recovered eating disorder patients. Biol. Psychiatry (1999) 46:292–299.
   PubMed Web of Science ®Google Scholar
• YANG YK, HARMON CM: Recent developments in our understanding of melanocortin system in the regulation of food intake. Obes. Rev (2003) 4:239–48.
   PubMedGoogle Scholar
• ADAN R, HILLEBRAND J, RUKE C et al: Melanocortin system and eating disorders. Ann. NY Acad. Sci. (2003) 994:267–274.
   PubMed Web of Science ®Google Scholar
• ARGYROPOULOS G, RANKINEN T, NEUFELD DR et al.: A polymorphism in the human agouti-related protein is associated with late-onset obesity. .1 Clin. Endocrinol Metab. (2002) 87:4198–4202.
   Google Scholar
• FAN W BOSTON BA, KESTERSON RA, HRUBY VJ, CONE RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165–168.
   PubMed Web of Science ®Google Scholar
• KALRA SP, HORVATH TL: Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Ann. NY Acad. Sci. (1998) 863:236–240.
   PubMed Web of Science ®Google Scholar
• CRAWELY JN: The role of galanin in feeding behavior. Neuropeptides (1999) 35:369–375.
   Google Scholar
• LEIBOWITZ SF: Brain peptides and obesity: pharmacologic treatment. Obes. Res. (1995) 3\(Suppl. 4):5735–5895.
   Google Scholar
• FRANK GK, KAYE WH, SAHU A, FERNSTROM J, MCCONAHA C: Could reduced cerebrospinal fluid (CSF) galanin contribute to restricted eating in anorexia nervosa? Neuropsychopharmacology (2001) 24:706–709.
   PubMed Web of Science ®Google Scholar
• BERRETTINI W, KAYE W SUNDERLAND T et al: Galanin immunoreactivity in human CSF: studies in eating disorders and Alzheimer's disease. Neuropsychobiology (1988) 19:64–68.
   PubMedGoogle Scholar
• INVITTI C, BRUNANI A, PASQUALINOTTO L et al.: Plasma galanin concentrations in obese, normal weight and anorectic women. Int. I Obes. Relat. Metab. Disord. (1995) 19:347–349.
   PubMed Web of Science ®Google Scholar
• BARANOWKA B, WOLINSKA-WITORT E, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, CHMIELOWKSA M: Plasma leptin, neuropeptide Y (NPY), and galanin concentrations in bulimia nervosa and anorexia nervosa. Neuroendocrinology Letters (2001) 22:356–358.
   PubMed Web of Science ®Google Scholar
• BARANOWSKA B, RADZIKOWSKA M, WASILEWSKA-DZIUBINSKA E, ROGUSKI K, BOROWIEC M: Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Obesity Metab. (2000) 2:99–103.
   PubMedGoogle Scholar
• BARANOWKSA B, WASILEWSKA-DZIUBINSKA E, RADZIKOWSKA M, PLONOWSKI A, ROGUSKI K: Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa. Metabolism (1997) 46:1384–1389.
   PubMed Web of Science ®Google Scholar
• DE MARINIS L, MANCINI A, VALLE D et al.: Effects of galanin on growth hormona and prolactin secretion in anorexia nervosa. Metabolism (2000) 49:155–159.
   PubMed Web of Science ®Google Scholar
• ERSPAMER V, ERPAMER GE INSELVINI M: Some pharmacological actions of alytesin and bombesin. Pharm. Pharmacol (1970) 22:875–876.
   PubMed Web of Science ®Google Scholar
• ANASTASI A, ERSPAMER V, BUCCI M: Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experkntia (1971) 27:166–167.
   PubMedGoogle Scholar
• MCDONALD TJ, JORNVALL H, NILSSON G et al.: Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem. Biophys. Res. Commun. (1979) 90:227–33.
   PubMed Web of Science ®Google Scholar
• MINAMINO N, KANGAWA K, MATUSO H: Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem. Biophys. Res. Commun. (1983) 114:541–548.
   PubMed Web of Science ®Google Scholar
• MINAMINO N, KANGAWA K, MATSUO H: Neuromedin B and neuromedin Ca. Two mammalian bombesin-like peptides identified in porcine spinal cord and brain. Ann. NY Acad. Sci. (1988) 547:373–390.
   Google Scholar
• GIBBS J, FASUER DJ, ROWE EA, ROLLS BJ, ROLLS ET, MADDISON SP: Bombesin suppresses feeding in rats. Nature. (1979) 282:208–10.
   PubMed Web of Science ®Google Scholar
• FATHI Z, BENYA RV, SHAPIRA H, JENSEN RT, BATTEY JF: The fifth transmembrane segment of the neuromedin B receptor is critical for high affinity neuromedin B binding. I Biol. Chem. (1993) 268:14622–14626.
   Web of Science ®Google Scholar
• YAMADA K, WADA E, SANTO-YAMADA Y, WADA K: Bombesin and its family of peptides: prospects for the treatment of obesity. Eur. Pharmacol (2002) 440:281–90
   PubMed Web of Science ®Google Scholar
• MERALI Z, MCINTOSH J, ANISMAN H: Role of bombesin related peptides in the control of food intake. Neuropeptides (1999) 33:376–386.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, GOSNELL BA, ROERIG JL et al: Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. Obes. Res. (2003) 11:599–602.
   PubMedGoogle Scholar
• FISMAN S, STEELE M, SHORT J, BYRNE T, LAVALLEE C: Case study: anorexia nervosa and autistic disorder in an adolescent girl.' Am. Acad. Child Adolesc. Psychiatry (1996) 35:937–940.
   PubMed Web of Science ®Google Scholar
• •Refs 185–198 - Atypical antipsychotic case studies in AN.
   Google Scholar
• HANSEN L: Olanzapine in the treatment of anorexia nervosa. BE J. Psychiatry (1999) 175:592.
   PubMed Web of Science ®Google Scholar
• JENSEN VS, MEJLHEDE A: Anorexia nervosa: treatment with olanzapine. Br. J. Psychiatry (2000) 177:187.
   Web of Science ®Google Scholar
• LA VIA MC, GRAY L, KAYE WH: Case reports of olanzapine treatment of anorexia nervosa. Int. J. Eat. Disord. (2000) 27:363–366.
   PubMed Web of Science ®Google Scholar
• NEWMAN-TOKER J: Risperidone in anorexia nervosa. J. Am. Acad. Child. Adolesc. Psychiatry (2000) 39:941–942.
   PubMed Web of Science ®Google Scholar
• GASKILL JA, TREAT TA, MCCABE EB, MARCUS MD: Does olanzapine affect the rate of weight gain among inpatients with eating disorders? Eat. Disord. Rev. (2001) 12 (6):1–2.
   Google Scholar
• MEHLER C, WEWETZER C, SCHULZE U, WARNKE A, THEISEN F, DITTMANN RW: Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur. Child. Asolesc. Psychiatry (2001) 10:151–157.
   PubMed Web of Science ®Google Scholar
• RUGGIERO GM, LAINI V, MAURI MC: A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog. Neuropsychopharmacol Biol. Psychiat. (2001) 25:1049–1059.
   PubMed Web of Science ®Google Scholar
• CARVER AE, MILLERS, HAGMAN J, SIGEL E: The use of risperidone for the treatment of anorexia nervosa. Academy of Eating Disorders Annual Meeting, Boston, USA, April (2002).
   Google Scholar
• POWERS PS, SANTANA CA, BANNON YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord. (2002) 32:146–154.
   PubMed Web of Science ®Google Scholar
• BOACHIE A, GOLDFIELD GS, SPETTIQUE W: Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int. J. Eat. Disord. (2003) 33(1):98–103.
   PubMed Web of Science ®Google Scholar
• BOSANAC P, BURROWS G, NORMAN T: Olanzapine in anorexia nervosa. Aust. NZI. Psychiatry (2003) 37:494.
   PubMed Web of Science ®Google Scholar
• ERCAN ES, COPKUNOL H, CYKOETHLU S, VARAN A: Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum. Psychopharmacol (2003) 18:401–403.
   PubMed Web of Science ®Google Scholar
• MALINA A, GASKILL J, MCCONAHA C et al: Olanzapine treatment of anorexia nervosa: a retrospective study. Int. J. Eat. Disord. (2003) 33:234–237.
   PubMed Web of Science ®Google Scholar